View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Cosmo Pharmaceuticals N.V.: 1 director

A director at Cosmo Pharmaceuticals N.V. bought 3,000 shares at 55.252CHF and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Baptiste Lebacq
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Fehmi Ben Naamane
  • Fehmi Ben Naamane

ODDO BHF Small & MIDCAP MORNING NEWS - 24/07/2024

The Platform Group (TPG) is a software company that is active across 20 industries through its digital platform solutions. Via its four segments (consumer goods, freight goods, industrial goods, service and retail goods), it serves both B2B and B2C customers. Given the growing revenues (2023-2026e CAGR +14.7%) and adjusted EBITDA margins (+270bp to 7.8% in 2026e vs 2023), as well as a solid financial profile (equity ratio >30%, average positive FCF of c.€ 8m for 2024e to 2026e) and un...

Fehmi Ben Naamane
  • Fehmi Ben Naamane

ODDO BHF Small & MIDCAP MORNING NEWS - 07/24/2024

The Platform Group (TPG) is a software company that is active across 20 industries through its digital platform solutions. Via its four segments (consumer goods, freight goods, industrial goods, service and retail goods), it serves both B2B and B2C customers. Given the growing revenues (2023-2026e CAGR +14.7%) and adjusted EBITDA margins (+270bp to 7.8% in 2026e vs 2023), as well as a solid financial profile (equity ratio >30%, average positive FCF of c.€ 8m for 2024e to 2026e) and un...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Cosmo Pharmaceuticals : First milestone payment received from Medtroni...

>First milestone payment from Medtronic received in February - Cosmo made a good start to the first half of the year for which the base of comparison was demanding. H1 revenues came to € 136m (vs € 43.7m last year) boosted by the $ 100m payment received from Medtronic in February. Growth was also driven by the revenues generated by Lialda and Cortiment as well as the two most recent launches Winlevi and GI Genius. However, comments on the royalties received from GI Ge...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Cosmo Pharmaceuticals : Un premier milestone de Medtronic reçu. Guidan...

>Un premier milestone de Medtronic payé en février - Cosmo a bien débuté cette première partie d’année alors que la base de comparaison était élevée. Les revenus du S1 ressortent à 136 M€ (vs 43.7 M€ l’année dernière) bénéficiant des 100 M$ reçus par Medtronic en février dernier. Cette croissance s’explique également par les revenus générés par Lialda et par Cortiment ainsi que ses deux derniers lancements Winlevi et GI Genius. Cependant des commentaires sur les redev...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Cosmo Pharmaceuticals : 3% adjustment to 2024 EBIT expectations antici...

>Update to 2023 accounts, upward adjustment for 2024e - Cosmo issued an update of its full-year results reported end-March. We particularly note a restatement for 2023 revenues which are now € 92.8m, vs € 96.7m. The difference stems from the reclassification of an asset booked in the P&L for close to € 4m. Also, with the new agreement with Medtronic, there is an adjustment of close to € 5.9m on costs for 2023. In contrast, this downward adjustment to the 2023 accounts...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch